Carmat
Carmat SA designs and develops total artificial heart for patients with advanced heart failure in France and internationally. The company offers Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.
Carmat (ALCAR) - Net Assets
Latest net assets as of December 2024: €-51.13 Million EUR
Based on the latest financial reports, Carmat (ALCAR) has net assets worth €-51.13 Million EUR as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€42.43 Million) and total liabilities (€93.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-51.13 Million |
| % of Total Assets | -120.5% |
| Annual Growth Rate | N/A |
| 5-Year Change | -754.02% |
| 10-Year Change | -3743.9% |
| Growth Volatility | 893.8 |
Carmat - Net Assets Trend (2009–2024)
This chart illustrates how Carmat's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Carmat (2009–2024)
The table below shows the annual net assets of Carmat from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-51.13 Million | -16.84% |
| 2023-12-31 | €-43.76 Million | -2528.52% |
| 2022-12-31 | €1.80 Million | +113.13% |
| 2021-12-31 | €-13.72 Million | -275.53% |
| 2020-12-31 | €7.82 Million | -67.88% |
| 2019-12-31 | €24.34 Million | +18.51% |
| 2018-12-31 | €20.54 Million | -64.10% |
| 2017-12-31 | €57.21 Million | +98.03% |
| 2016-12-31 | €28.89 Million | +1958.75% |
| 2015-12-31 | €1.40 Million | -81.93% |
| 2014-12-31 | €7.76 Million | +7.41% |
| 2013-12-31 | €7.23 Million | -27.29% |
| 2012-12-31 | €9.94 Million | -63.03% |
| 2011-12-31 | €26.89 Million | +73.57% |
| 2010-12-31 | €15.49 Million | +280.26% |
| 2009-12-31 | €4.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Carmat's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9376999600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €1.78 Million | % |
| Other Components | €45.58 Million | % |
| Total Equity | €-51.13 Million | 100.00% |
Carmat Competitors by Market Cap
The table below lists competitors of Carmat ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BioNexus Gene Lab Corp Common stock
NASDAQ:BGLC
|
$3.28 Million |
|
PT Dewi Shri Farmindo Tbk
JK:DEWI
|
$3.28 Million |
|
Truong Long Engineering and Auto JSC
VN:HTL
|
$3.29 Million |
|
SEI
BK:SEI
|
$3.29 Million |
|
TEMPUS RESOURCES LTD
F:4W0
|
$3.28 Million |
|
Hiper Global Ltd
TA:HIPR
|
$3.28 Million |
|
Tissue Repair Ltd
AU:TRP
|
$3.28 Million |
|
Master Pack Group Bhd
KLSE:7029
|
$3.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Carmat's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -45,114,000 to -51,131,000, a change of -6,017,000.
- Net loss of 51,400,000 reduced equity.
- Share repurchases of 41,894,000 reduced equity.
- New share issuances of 41,894,000 increased equity.
- Other comprehensive income decreased equity by 68,000.
- Other factors increased equity by 45,451,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-51.40 Million | -100.53% |
| Share Repurchases | €41.89 Million | -81.93% |
| Share Issuances | €41.89 Million | +81.93% |
| Other Comprehensive Income | €-68.00K | -0.13% |
| Other Changes | €45.45 Million | +88.89% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Carmat's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | €1.04 | €0.10 | x |
| 2010-12-31 | €3.95 | €0.10 | x |
| 2011-12-31 | €6.52 | €0.10 | x |
| 2012-12-31 | €2.39 | €0.10 | x |
| 2013-12-31 | €1.69 | €0.10 | x |
| 2014-12-31 | €1.77 | €0.10 | x |
| 2015-12-31 | €0.31 | €0.10 | x |
| 2016-12-31 | €4.79 | €0.10 | x |
| 2017-12-31 | €6.34 | €0.10 | x |
| 2018-12-31 | €2.21 | €0.10 | x |
| 2019-12-31 | €1.93 | €0.10 | x |
| 2020-12-31 | €0.60 | €0.10 | x |
| 2021-12-31 | €-0.88 | €0.10 | x |
| 2022-12-31 | €0.07 | €0.10 | x |
| 2023-12-31 | €-1.98 | €0.10 | x |
| 2024-12-31 | €-2.24 | €0.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Carmat utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -734.29%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-394.76%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -115.90% | 0.00% | 0.00x | 1.49x | €-5.13 Million |
| 2010 | -49.94% | -153.24% | 0.24x | 1.36x | €-9.29 Million |
| 2011 | -49.98% | 0.00% | 0.00x | 1.39x | €-16.13 Million |
| 2012 | -172.91% | 0.00% | 0.00x | 1.98x | €-18.18 Million |
| 2013 | -202.60% | -509.63% | 0.13x | 3.04x | €-15.37 Million |
| 2014 | -235.22% | -182630.56% | 0.00x | 1.81x | €-19.04 Million |
| 2015 | -1250.42% | -122270.11% | 0.00x | 6.16x | €-17.69 Million |
| 2016 | -79.55% | -13270.53% | 0.00x | 1.30x | €-25.87 Million |
| 2017 | -51.09% | -104385.39% | 0.00x | 1.22x | €-34.95 Million |
| 2018 | -203.18% | -298064.76% | 0.00x | 1.79x | €-43.78 Million |
| 2019 | -175.22% | -304633.37% | 0.00x | 2.65x | €-45.08 Million |
| 2020 | -472.79% | -410700.00% | 0.00x | 7.65x | €-37.74 Million |
| 2021 | 0.00% | -2775.82% | 0.03x | 0.00x | €-60.50 Million |
| 2022 | -3257.34% | -15559.71% | 0.00x | 51.62x | €-53.85 Million |
| 2023 | 0.00% | -1891.47% | 0.05x | 0.00x | €-49.36 Million |
| 2024 | 0.00% | -734.29% | 0.16x | 0.00x | €-46.29 Million |
Industry Comparison
This section compares Carmat's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $42,035,434
- Average return on equity (ROE) among peers: -36.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Carmat (ALCAR) | €-51.13 Million | -115.90% | N/A | $3.28 Million |
| Affluent Medical SAS (AFME) | $33.83 Million | -45.01% | 0.77x | $31.64 Million |
| Biosynex (ALBIO) | $124.31 Million | -29.72% | 0.94x | $7.06 Million |
| Bluelinea SA (ALBLU) | $1.96 Million | -41.72% | 0.71x | $6.02 Million |
| Diagnostic Medical Systems SA (ALDMS) | $13.72 Million | -36.04% | 2.73x | $13.39 Million |
| Eurobio Scientific SA (ALERS) | $175.17 Million | 2.76% | 0.81x | $5.52 Million |
| Ikonisys SA (ALIKO) | $20.01 Million | -2.85% | 0.13x | $9.76 Million |
| Implanet SA (ALIMP) | $3.54 Million | -99.97% | 3.09x | $6.96 Million |
| Mediantechn (ALMDT) | $0.00 | 0.00% | 0.00x | $86.92 Million |
| Spineguard (ALSGD) | $5.77 Million | -78.70% | 0.48x | $5.70 Million |